Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation

Biochemical Pharmacology

Volumn 52, Issue 11, 1996, Pages 1741-1747

  Gasdaska, John R ^a   Kirkpatrick, D Lynn ^b   Montfort, William ^c   Kuperus, Miles ^b   Hill, Simon R ^a   Berggren, Margareta ^a   Powis, Garth ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF REGINA   (Canada)

^c University of Arizona ^*  (United States)

Author keywords

growth factor; homodimer; oxidation; thioredoxin

Indexed keywords

CYSTEINE; DIMER; DITHIOTHREITOL; GROWTH FACTOR; MONOMER; MUTANT PROTEIN; OXIDIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ARTICLE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; OXIDATION; OXIDATION REDUCTION STATE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; REDUCTION;

GROWTH SUBSTANCES; HUMANS; OXIDATION-REDUCTION; POINT MUTATION; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXIN; TUMOR CELLS, CULTURED;

EID: 0030582835     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00595-3     Document Type: Article

References (35)

1. 1. Holmgren A, Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
2. 2. Luthman M and Holmgren A, Rat liver chioredoxin and thioredoxin reductase: purification and characterization. Biochem 21: 6628-6633, 1982.
3. 3. Laurent TC, Moore EC and Reichard P, Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredixon, the hydrogen donor from Escherichia coli B. J Biol Chem 239: 3436-3444, 1964.
4. 4. Fountoulakis M, Unfolding intermediates of the extracellular domain of the interferon gamma receptor. J Biol Chem 267: 7095-7100, 1992.
5. 5. Kistner A, Sanders D and Habermann E, Disulfide formation in reduced tetanus toxin by thioredoxin: The pharmacological role of interchain covalent and noncovalent bonds. Toxicon 31: 1423-1434, 1993.
6. 6. Silverman RB and Nandi DL, Reduced thioredoxin: A possible physiological cotactor for vitamin K epoxide reductase. Further support for an active site disulfide. Biochem Biophys Res Commun 155: 1248-1254, 1988.
7. 7. Hayashi T, Ueno Y and Okamoto T, Oxidoreductive regulation of nuclear factor KB: Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268: 11380-11388, 1993.
8. 8. Galter D, Mihm S and Dröge W, Distinct effects of glutathione disulfide on the nuclear transcription factors KB and the activator protein-1. Eur J Biochem 221: 639-648, 1994.
9. 9. Grippo JF, Tienrungroj W, Dahmer MK, Housley PR and Pratt WB, Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 258: 13658-13664, 1983.
10. 10. Cromlish JA and Roeder RG, Human transcription factor IIIC (TFIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J Biol Chem 264: 18100-18109, 1989.
11. 11. Freedman RB, Hirst TR and Tuite MF, Protein disulphide isomerase: building bridges in protein folding. Trends Biochem Sci 19: 331-336, 1994.
12. 12. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J and Powis G, Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res (in press).
13. 13. Gasdaska PY, Oblong JE, Cotgreave IA and Powis G, The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1218: 292-296, 1994.
14. 14. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto Y, Nanbu Y, Fujii S, Ozawa K and Yodoi J, Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69: 2091-2097, 1992.
15. 15. Gallegos A, Gasdaska JR, Goodman D, Gasdaska PY, Berggren M, Briehl MM and Powis G, Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res (in press).
16. 16. Oblong JE, Berggren M, Gasdaska PY and Powis G, Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem 269: 117H-11720, 1994.
17. 17. Wakasugi N, Tagaya Y, Wakasugi A, Mitsui M, Maeda M, Yodoi J and Tursz T, Adult T-cell leukemia-derived factor/ Thioredoxin produced by both human T-lymphotropic virus type 1 and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2. Proc Natl Acad Sci USA 87: 8282-8286, 1990.
18. 18. Gasdaska JR, Berggren M and Powis G, Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6: 1643-1650, 1995.
19. 19. Rubartelli A, Bajetto A, Allavena G, Wollman E and Sitia R, Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 24161-24164,1992.
20. 20. Weichsel A, Gasdaska JR, Powis G and Montfort WR, Crystal structures of reduced, oxidized, and mutated human thioredoxins: Evidence for a regulatory homodimer. Structure 4: 735-751, 1996.
21. 21. Forman-Kay JD, Clore GM, Wingfield PT and Gronenborn AM, High-resolution three-dimensional structure of reduced recombinant human thioredoxin in solution. Biochem 30: 2685-2698, 1991.
22. 22. Studier FW, Rosenberg AH, Dunn JJ and Dubendorff JW, Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 185: 60-89, 1991.
23. 23. Oblong JE, Gasdaska PY, Sherrill K and Powis G, Purification of human thioredoxin reductase: Properties and characterization by absorption and circular dichroism spectroscopy. Biochem 32: 7271-7277, 1993.
24. 24. Poyer JL and McCay PB, Reduced triphosphopyridine nucleotide oxidase-catalyzed alterations of membrane phospholipids. J Biol Chem 246: 263-269, 1971.
25. 25. Kosower NS and Kosower EM, Diamide: An oxidant probe for thiols. Methods Enzymol 251: 123-132, 1995.
26. 26. Gilbert HF, Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol 251: 8-30, 1995.
27. 27. Creighton TE, Disulfide bond formation in proteins. Methods Enzymol 107: 305-329, 1984.
28. 28. Ellman GL, Tissue Sulfhydryl groups. Arch Biochem Biophys 82: 70-77, 1959.
29. 29. Claiborne A, Miller H, Parsonage D and Ross RP, Protein-sulfenic acid stabilization and function in enzyme catalysis and gene regulation. FASEB J 7: 1483-1490, 1993.
30. 30. Poole LB and Claiborne A, The non-flavin redox center of the streptococcal NADH peroxidase II, Evidence for a stabilized cystein-sulfenic acid. J Biol Chem 264: 12330-12338, 1989.
31. 31. Weissman JS and Kim PS, Reexamination of the folding of BPTI: Predominance of native intermediates. Science 253: 1386-1393, 1995.
32. 32. Kraulis PJ, MOLESCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Cryst 24: 946-950, 1991.
33. 33. Page DL, Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15: 334-349, 1991.
34. 34. Ren X, Bjornstedt M, Shen B, Ericson ML and Holmgren A, Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochem 32: 9701-9705, 1993.
35. 35. Sato N, Iwata S, Nakamura K, Hori T, Mori K and Yodoi J, Thiol-mediated redox regulation of apoptosis. J Immunol 154: 3194-3203, 1995.